Professor Moshe Many to leave post as Vice Chairman effective January 1, 2014, will remain a member of the board
10 December 2013 | By Teva
Amir Elstein to succeed Professor Moshe Many...
List view / Grid view
News
Novo Nordisk reported to the police by the Danish Financial Supervisory Authority for violating disclosure obligation
10 December 2013 | By Novo Nordisk
The reporting relates to the company’s receipt of a Complete Response Letter from the US Food and Drug Administration...
Merck advances development program for investigational Alzheimer’s Disease Therapy, MK-8931
10 December 2013 | By Merck
The DMC recommendation was made following a planned analysis of interim safety data that included a safety cohort of 200 patients treated with MK-8931 for at least 3 months...
New data analyses show consistent efficacy and safety profile of Pradaxa® in broad range of patients with acute deep vein thrombosis or pulmonary embolism
10 December 2013 | By Boehringer Ingelheim
The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics...
Phase 3 data show Daiichi Sankyo’s once-daily edoxaban lowered incidence of VTE recurrence and clinically relevant bleeding
10 December 2013 | By Daiichi Sankyo Company
This analysis of VTE patients with cancer was presented at the 2013 American Society of Hematology Annual Meeting and Exposition...
Janssen announces first-of-its-kind Drug Donation Program for HIV treatment-experienced children
9 December 2013 | By Johnson & Johnson
Sub-Saharan African Ministries of Health invited to submit expression of interest to participate in new effort donation program to be part of broader initiative to raise awareness and action...
Novartis supplies MenB vaccine, Bexsero®, to Princeton University to help protect students from potentially deadly outbreak
9 December 2013 | By Novartis
Novartis supplies MenB vaccine for a vaccination program at Princeton, following approvals by health authorities and University officials...
AstraZeneca donates Brixham Environmental Laboratory to Plymouth University
9 December 2013 | By AstraZeneca
The donation of the facility and its equipment will ensure that the laboratory continues to serve scientific and research purposes...
Gilead announces pivotal phase 2 data for idelalisib in refractory indolent non-hodgkin’s lymphoma
8 December 2013 | By Gilead Sciences
In this study, single-agent treatment with idelalisib achieved an overall response rate of 57 percent with a median duration of response of 12.5 months...
Novartis investigational compound LBH589 significantly extended time without disease progression in Phase III multiple myeloma study
6 December 2013 | By Novartis
LBH589 has potential to be the first in its class of anticancer agents available to patients with multiple myeloma...
European Commission approves Fluenz Tetra for the prevention of seasonal influenza in children
6 December 2013 | By AstraZeneca
Fluenz Tetra is a nasally administered four-strain live attenuated influenza vaccine for the prevention of influenza in children and adolescents from 24 months up to 18 years of age...
GSK launches global consortium with six renowned cancer research centres
5 December 2013 | By GlaxoSmithKline
GlaxoSmithKline plc announced the formation of the Oncology Clinical and Translational Consortium...
Nova Laboratories announces FDA filing of New Drug Application for the treatment of childhood acute lymphoblastic leukemia
4 December 2013 | By Nova Laboratories
The product has been granted orphan drug designation by the FDA, a status given to a product intended for the treatment of a rare disease or condition...
Teva and Takeda announce agreement for glatiramer acetate for multiple sclerosis treatment in Japan
4 December 2013 | By Teva Pharmaceutical Industries
Glatiramer acetate for injection is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis...
Novartis to highlight long-term data, innovative pipeline for patients with hematologic diseases and breast cancer at ASH and SABCS
4 December 2013 | By Novartis
"Cancer treatment has been revolutionized by targeted therapies, which have established a highly successful approach to the management of many cancers..."
